PerkinElmer, Inc. (NYSE:PKI) Receives Consensus Rating of “Hold” from Analysts

Shares of PerkinElmer, Inc. (NYSE:PKI – Get Rating) have received an average recommendation of “Hold” from the twelve brokerages that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $165.90.

A number of research analysts recently issued reports on PKI shares. Cowen upgraded PerkinElmer from a “market perform” rating to an “outperform” rating and decreased their target price for the company from $192.00 to $164.00 in a report on Tuesday, December 6th. Credit Suisse Group cut their price target on PerkinElmer from $175.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, November 14th. StockNews.com cut PerkinElmer from a “buy” rating to a “hold” rating in a research note on Thursday, November 10th. Cowen upgraded PerkinElmer from a “market perform” rating to an “outperform” rating and set a $164.00 price target on the stock in a research note on Tuesday, December 6th. Finally, Robert W. Baird cut their price target on PerkinElmer from $202.00 to $178.00 in a research note on Wednesday, November 9th.

PerkinElmer Trading Down 4.2 %

NYSE:PKI opened at $134.87 on Wednesday. The firm has a market cap of $17.02 billion, a PE ratio of 27.52, a price-to-earnings-growth ratio of 0.50 and a beta of 1.12. The stock has a fifty day moving average price of $138.10 and a 200 day moving average price of $137.30. PerkinElmer has a 12-month low of $113.46 and a 12-month high of $190.56. The company has a current ratio of 2.10, a quick ratio of 1.84 and a debt-to-equity ratio of 0.55.

PerkinElmer (NYSE:PKI – Get Rating) last released its earnings results on Tuesday, November 8th. The medical research company reported $1.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.48 by $0.03. The firm had revenue of $711.80 million during the quarter, compared to analyst estimates of $1.03 billion. PerkinElmer had a return on equity of 15.58% and a net margin of 13.60%. Sell-side analysts anticipate that PerkinElmer will post 7.9 earnings per share for the current fiscal year.

Insider Transactions at PerkinElmer

In other news, insider Tajinder S. Vohra sold 1,663 shares of PerkinElmer stock in a transaction dated Tuesday, December 20th. The stock was sold at an average price of $138.85, for a total transaction of $230,907.55. Following the sale, the insider now owns 17,205 shares in the company, valued at $2,388,914.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.52% of the company’s stock.

Institutional Trading of PerkinElmer

Hedge funds and other institutional investors have recently made changes to their positions in the company. Accurate Wealth Management LLC acquired a new stake in shares of PerkinElmer during the fourth quarter worth about $27,000. Clear Street Markets LLC increased its position in shares of PerkinElmer by 417.6% during the second quarter. Clear Street Markets LLC now owns 264 shares of the medical research company’s stock worth $38,000 after purchasing an additional 213 shares in the last quarter. Private Trust Co. NA acquired a new stake in shares of PerkinElmer during the second quarter worth about $42,000. FourThought Financial LLC acquired a new position in PerkinElmer in the 3rd quarter valued at about $42,000. Finally, Crewe Advisors LLC increased its position in PerkinElmer by 546.8% in the 2nd quarter. Crewe Advisors LLC now owns 401 shares of the medical research company’s stock valued at $57,000 after acquiring an additional 339 shares during the period. Institutional investors and hedge funds own 85.22% of the company’s stock.

PerkinElmer Company Profile

(Get Rating)

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.